Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2004

View Archived Issues

Studies assess metformin combination therapies in type 2 diabetes

Clinical efficacy of repaglinide discussed at European Diabetes Congress

Boehringer Ingelheim in new GPCR research collaboration

Epix Medical changes name to Epix Pharmaceuticals

Immune Response Corp. transfers cancer cell line vaccines rights to NovaRx

GTI-2040 and capecitabine reported to be well tolerated in advanced kidney cancer

Two series of glucokinase activators presented by Lilly scientists

Novel HIV integrase inhibitors prepared and tested at Pfizer

New factor Xa/factor VIIa inhibitors covered by Merck KGaA patent

Incyte patent covers novel antitumor agents targeting JNK signaling pathways

s-CD23 production inhibitors newly developed at GSK

New MMP-13 inhibitors and their use reported by Pfizer scientists

New PDE7 inhibitors claimed by Almirall Prodesfarma researchers

ENT-103 development update

Enrollment target reached in STRIDE-2 study of Thelin

Entereg NDA accepted for review

Insmed's rhIGFBP-3 enters phase I study

Ventavis NDA accepted for priority review

HGS-ETR1 advanced into phase II

Phase II Hemospan study opens in Sweden

Phase IIb study evaluates VEGF-2 for severe cardiovascular disease

New data on the pharmacokinetics and clinical efficacy of roflumilast

Phase III study of INKP-102 commences enrollment

CKD-501 reduces glucose levels in model of insulin resistance

Advanced Viral Research plans IND filing for injectable AVR-118

Statins reported to improve survival after lung transplantation

Assessment of survival of advanced NSCLC patients treated with gefitinib

Modified-release indiplon shows efficacy in elderly patients with insomnia

Second milnacipran phase III study for FMS scheduled for Q4

Enrollment begins for phase III study of central precocious puberty implant

Positive one-year data for NX-1207 in BPH

Interim results of QTc study of ISA-247

New phase II study investigates HspE7 for internal genital warts

Dosing completed in LAB's first clinical study of GHRH analogue

Merck & Co.'s near-term pipeline shows promise

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...